Observational Cohort Study of Evolving Epidemiologic, Clinical, and Virologic Features of Monkeypox in Southern France
We enrolled 136 patients with laboratory-confirmed monkeypox during June 4–August 31, 2022, at the University Hospital Institute Méditerranée Infection in Marseille, France. The median patient age was 36 years (interquartile range 31–42 years). Of 136 patients, 125 (92%) were men who have sex with men, 15 (11%) reported previous smallpox vaccinations, and 21 (15.5%) were HIV-positive. The most frequent lesion locations were the genitals (68 patients, 53%), perianal region (65 patients, 49%), and oral/perioral area (22 patients, 17%). Lesion locations largely corresponded with the route of contamination. Most (68%) patients had isolated anal, genital, or oral lesions when they were first seen, including 56 (61%) who had <1 positive site without a visible lesion. Concurrent sexually transmitted infections were diagnosed in 19 (15%) patients, and 7 patients (5%) were asymptomatic. We recommend vaccination campaigns, intensified testing for sexually transmitted infections, and increased contact tracing to control the ongoing monkeypox outbreak..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Emerging Infectious Diseases - 28(2022), 12, Seite 2409-2415 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nadim Cassir [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Infectious and parasitic diseases |
|---|
| doi: |
10.3201/eid2812.221440 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ026601036 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ026601036 | ||
| 003 | DE-627 | ||
| 005 | 20230501182530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid2812.221440 |2 doi | |
| 035 | |a (DE-627)DOAJ026601036 | ||
| 035 | |a (DE-599)DOAJf3613d8a0422461aa8fce39bbdf0b2b7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Nadim Cassir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Observational Cohort Study of Evolving Epidemiologic, Clinical, and Virologic Features of Monkeypox in Southern France |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a We enrolled 136 patients with laboratory-confirmed monkeypox during June 4–August 31, 2022, at the University Hospital Institute Méditerranée Infection in Marseille, France. The median patient age was 36 years (interquartile range 31–42 years). Of 136 patients, 125 (92%) were men who have sex with men, 15 (11%) reported previous smallpox vaccinations, and 21 (15.5%) were HIV-positive. The most frequent lesion locations were the genitals (68 patients, 53%), perianal region (65 patients, 49%), and oral/perioral area (22 patients, 17%). Lesion locations largely corresponded with the route of contamination. Most (68%) patients had isolated anal, genital, or oral lesions when they were first seen, including 56 (61%) who had <1 positive site without a visible lesion. Concurrent sexually transmitted infections were diagnosed in 19 (15%) patients, and 7 patients (5%) were asymptomatic. We recommend vaccination campaigns, intensified testing for sexually transmitted infections, and increased contact tracing to control the ongoing monkeypox outbreak. | ||
| 650 | 4 | |a monkeypox | |
| 650 | 4 | |a viruses | |
| 650 | 4 | |a sexually transmitted infections | |
| 650 | 4 | |a zoonoses | |
| 650 | 4 | |a public health policy | |
| 650 | 4 | |a vaccination | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Florian Cardona |e verfasserin |4 aut | |
| 700 | 0 | |a Hervé Tissot-Dupont |e verfasserin |4 aut | |
| 700 | 0 | |a Christiane Bruel |e verfasserin |4 aut | |
| 700 | 0 | |a Barbara Doudier |e verfasserin |4 aut | |
| 700 | 0 | |a Salima Lahouel |e verfasserin |4 aut | |
| 700 | 0 | |a Karim Bendamardji |e verfasserin |4 aut | |
| 700 | 0 | |a Céline Boschi |e verfasserin |4 aut | |
| 700 | 0 | |a Sarah Aherfi |e verfasserin |4 aut | |
| 700 | 0 | |a Sophie Edouard |e verfasserin |4 aut | |
| 700 | 0 | |a Jean-Christophe Lagier |e verfasserin |4 aut | |
| 700 | 0 | |a Philippe Colson |e verfasserin |4 aut | |
| 700 | 0 | |a Philippe Gautret |e verfasserin |4 aut | |
| 700 | 0 | |a Pierre-Edouard Fournier |e verfasserin |4 aut | |
| 700 | 0 | |a Philippe Parola |e verfasserin |4 aut | |
| 700 | 0 | |a Philippe Brouqui |e verfasserin |4 aut | |
| 700 | 0 | |a Bernard La-Scola |e verfasserin |4 aut | |
| 700 | 0 | |a Matthieu Million |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Emerging Infectious Diseases |d Centers for Disease Control and Prevention, 2003 |g 28(2022), 12, Seite 2409-2415 |w (DE-627)DOAJ000014966 |x 10806059 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:12 |g pages:2409-2415 |
| 856 | 4 | 0 | |u https://doi.org/10.3201/eid2812.221440 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f3613d8a0422461aa8fce39bbdf0b2b7 |z kostenfrei |
| 856 | 4 | 0 | |u https://wwwnc.cdc.gov/eid/article/28/12/22-1440_article |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1080-6040 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1080-6059 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 12 |h 2409-2415 | ||